His and HERs

The problem with prostate cancer is that tumors originally dependent on androgen become hormone-refractory after sustained anti-androgen therapy. But a Nature Medicine paper suggests that overexpression of the HER-2/neu receptor tyrosine kinase is implicated in the mechanism of androgen independence, thereby opening a potential new treatment for the disease.

The finding thus points to a possible new market for Genentech Inc.'s Herceptin trastuzumab anti-HER-2 antibody as well as